ArticleJAMA network open2026
Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
Abstract
Importance: Docetaxel has been a standard treatment for metastatic castration-resistant prostate cancer (mCRPC) since 2004. Cabazitaxel, a related taxane, was approved in 2010 for patients with mCRPC who had been previously treated with docetaxel. The comparative effectiveness of docetaxel rechallenge vs switching to cabazitaxel after prior docetaxel for mCRPC remains unclear. Objective: To compare the clinical outcomes associated with docetaxel rechallenge vs cabazitaxel in patients with mCRPC who did not experience disease progression during prior administration of docetaxel in the mCRPC setting. Design, Setting, and Participants: This retrospective cohort study was conducted in the nationwide Veterans Affairs health care system, using inverse probability of treatment weighting to control for potential confounders. Patients who were diagnosed with chemonaive mCRPC between January 1, 2010, and December 31, 2023, received initial docetaxel treatment, and did not experience disease progression were eligible to participate. Exposures: Treatment with docetaxel rechallenge or cabazitaxel. Main Outcomes and Measures: The primary outcome was overall survival (OS) from the initiation of the second course of taxane, which was compared in patients treated with docetaxel rechallenge vs cabazitaxel using weighted Kaplan-Meier analysis and Cox proportional hazards regression models. Secondary outcomes included prostate-specific antigen response, time to next systemic treatment or death, and subsequent treatments received. Results: A total of 669 patients (407 receiving cabazitaxel and 262 receiving docetaxel rechallenge) with a median age of 72 (IQR, 67-77) years were included. Patients treated with docetaxel rechallenge had a significantly longer OS (median, 12.3 [IQR, 10.5-13.8] months) compared with those treated with cabazitaxel (median, 9.6 [IQR, 8.6-11.1] months), with a hazard ratio of 0.81 (95% CI, 0.55-0.99; P = .04). Descriptive analysis of secondary outcomes was consistent with this finding, including prostate-specific antigen response (weighted 9.8% achieving reduction of 90% or more in the docetaxel rechallenge group vs 3.0% in the cabazitaxel group) and time to next treatment or death (median, 10.7 [IQR, 7.8-12.7] months in the docetaxel rechallenge group vs 8.9 [IQR, 7.1-10.5 months] in the cabazitaxel group). Use of platinum, immunotherapy, or poly (ADP-ribose) polymerase inhibitors was similar between patients treated with cabazitaxel and docetaxel rechallenge. Conclusions and Relevance: In this cohort study of patients with mCRPC, docetaxel rechallenge was associated with improved OS compared with cabazitaxel among patients who did not experience disease progression during prior docetaxel for mCRPC. These findings support docetaxel rechallenge as a treatment option for patients in this scenario.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.